Titan Pharmaceuticals Inc logo

Titan Pharmaceuticals Inc

$ 1.09 +0.03 (+2.83%) 01:44 PM EST
P/E:
At Loss
P/B:
2.92
Market Cap:
$ 16.55M
Enterprise V:
$ 9.26M
Volume:
19.66K
Avg Vol (2M):
76.97K
Also Trade In:
Volume:
19.66K
Market Cap $:
16.55M
PE Ratio:
At Loss
Avg Vol (2-Month):
76.97K
Enterprise Value $:
9.26M
PB Ratio:
2.92
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.
Name Current Vs Industry Vs History
Cash-To-Debt 26.2
Equity-to-Asset 0.68
Debt-to-Equity 0.04
Debt-to-EBITDA -0.03
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -63.53
Distress
Grey
Safe
Beneish M-Score -99999999.99
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 29.72
9-Day RSI 29.52
14-Day RSI 33.72
6-1 Month Momentum % 56.5
12-1 Month Momentum % -21.39

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.06
Quick Ratio 2.87
Cash Ratio 2.54
Days Sales Outstanding 78.71

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -183.8

Financials

TTNP's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:TTNP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.741
EPS (TTM) ($) -0.87
Beta 1.23
Volatility % 160.23
14-Day RSI 33.72
14-Day ATR ($) 0.116691
20-Day SMA ($) 1.25335
12-1 Month Momentum % -21.39
52-Week Range ($) 0.3496 - 2.03
Shares Outstanding (Mil) 14.63

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Titan Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Titan Pharmaceuticals Inc Analysis

Share your research

Headlines

See More
No news.